Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Allogeneic peripheral blood mononuclear cells incubated ex vivo with 16, 16-dimethyl prostaglandin E2 and dexamethasone

EU orphan designation number: EU/3/16/1774   
Active ingredient: Allogeneic peripheral blood mononuclear cells incubated ex vivo with 16, 16-dimethyl prostaglandin E2 and dexamethasone
Indication: Treatment in haematopoietic stem cell transplantation
Sponsor: Fate Therapeutics Ltd
Lower Ground Floor, One George Yard, London ECSV 9DF, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
22/11/2016 Orphan designation EMA/OD/149/16 7616 of 18/11/2016
27/06/2017 Change of name and/or address of sponsor